FDA rejects neffy epinephrine nasal spray for severe allergic reactions pending further trial data
CBSN
The Food and Drug Administration declined on Tuesday to approve neffy, an epinephrine nasal spray from drugmaker ARS Pharmaceuticals, keeping the first needle-free option for Americans to treat severe allergic reactions off the market pending more trial data.
ARS had expected the FDA to approve neffy for use in adults and children who weigh more than 30 kilograms, or around 66 pounds. The spray would have required a prescription, similar to EpiPens and other epinephrine injections that are currently used to treat anaphylaxis.
Epinephrine is crucial in an emergency to treat potentially life-threatening allergic reactions. The new spray, if eventually approved, would provide a welcome alternative for many families of children with severe allergies who'd rather avoid needles.
President Biden on Monday signed into law a defense bill that authorizes significant pay raises for junior enlisted service members, aims to counter China's growing power and boosts overall military spending to $895 billion despite his objections to language stripping coverage of transgender medical treatments for children in military families.
It's Christmas Eve, and Santa Claus is suiting up for his annual voyage from the North Pole to households around the world. In keeping with decades of tradition, the North American Aerospace Command, or NORAD, will once again track Santa's journey to deliver gifts to children before Christmas 2024, using an official map that's updated consistently to show where he is right now.